Hainan Shuangcheng Pharmaceuticals Co., Ltd.'s (SZSE:002693) 39% Share Price Plunge Could Signal Some Risk

Unfortunately for some shareholders, the Hainan Shuangcheng Pharmaceuticals Co., Ltd. (SZSE:002693) share price has dived 39% in the last thirty days, prolonging recent pain. Looking at the bigger picture, even after this poor month the stock is up 38% in the last year.

Although its price has dipped substantially, you could still be forgiven for thinking Hainan Shuangcheng Pharmaceuticals is a stock to steer clear of with a price-to-sales ratios (or "P/S") of 19.7x, considering almost half the companies in China's Pharmaceuticals industry have P/S ratios below 3.5x. However, the P/S might be quite high for a reason and it requires further investigation to determine if it's justified.

View our latest analysis for Hainan Shuangcheng Pharmaceuticals

What Does Hainan Shuangcheng Pharmaceuticals' P/S Mean For Shareholders?

As an illustration, revenue has deteriorated at Hainan Shuangcheng Pharmaceuticals over the last year, which is not ideal at all. Perhaps the market believes the company can do enough to outperform the rest of the industry in the near future, which is keeping the P/S ratio high. If not, then existing shareholders may be quite nervous about the viability of the share price.

We don't have analyst forecasts, but you can see how recent trends are setting up the company for the future by checking out our free report on Hainan Shuangcheng Pharmaceuticals' earnings, revenue and cash flow.

How Is Hainan Shuangcheng Pharmaceuticals' Revenue Growth Trending?

The only time you'd be truly comfortable seeing a P/S as steep as Hainan Shuangcheng Pharmaceuticals' is when the company's growth is on track to outshine the industry decidedly.

Taking a look back first, the company's revenue growth last year wasn't something to get excited about as it posted a disappointing decline of 30%. This means it has also seen a slide in revenue over the longer-term as revenue is down 45% in total over the last three years. Therefore, it's fair to say the revenue growth recently has been undesirable for the company.

Comparing that to the industry, which is predicted to deliver 64% growth in the next 12 months, the company's downward momentum based on recent medium-term revenue results is a sobering picture.

With this information, we find it concerning that Hainan Shuangcheng Pharmaceuticals is trading at a P/S higher than the industry. It seems most investors are ignoring the recent poor growth rate and are hoping for a turnaround in the company's business prospects. Only the boldest would assume these prices are sustainable as a continuation of recent revenue trends is likely to weigh heavily on the share price eventually.

The Bottom Line On Hainan Shuangcheng Pharmaceuticals' P/S

A significant share price dive has done very little to deflate Hainan Shuangcheng Pharmaceuticals' very lofty P/S. Typically, we'd caution against reading too much into price-to-sales ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.

We've established that Hainan Shuangcheng Pharmaceuticals currently trades on a much higher than expected P/S since its recent revenues have been in decline over the medium-term. When we see revenue heading backwards and underperforming the industry forecasts, we feel the possibility of the share price declining is very real, bringing the P/S back into the realm of reasonability. Should recent medium-term revenue trends persist, it would pose a significant risk to existing shareholders' investments and prospective investors will have a hard time accepting the current value of the stock.

You always need to take note of risks, for example - Hainan Shuangcheng Pharmaceuticals has 2 warning signs we think you should be aware of.

If you're unsure about the strength of Hainan Shuangcheng Pharmaceuticals' business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.